Junta Gral Jun2025

Jun 23, 2025 | Investors

CONVOCATORIA DE JUNTA GENERAL ORDINARIA DE LA SOCIEDAD CANCERAPPY, S.L.

El órgano de administración de la sociedad Cancerappy, S.L. (en adelante, la “Sociedad”), de conformidad con la normativa legal y estatutaria en vigor, en fecha 26 de mayo de 2025, ha acordado convocar a los señores socios de esta Sociedad a la Junta General Ordinaria de socios, que tendrá lugar en la sede social de la Sociedad el próximo 26 de junio a las 19:00 horas, al objeto de deliberar y resolver acerca de los puntos comprendidos en el siguiente,

The board of the company Cancerappy, S.L. (hereinafter, the “Company”), in accordance with the legal and statutory regulations in force, on May 26th, 2024, has agreed to summon the partners of this Company to the Ordinary General Shareholders’ Meeting, which will take place at the Company’s headquarters next June 26th at 7:00 p.m., in order to deliberate and decide on the points included in the following,

Integrating artificial intelligence in drug discovery and early drug development

Integrating artificial intelligence in drug discovery and early drug development

Apr 8, 2025 | Artificial Intelligence, Cancer Reseach, Publications

biospain_cancerappy

Cancerappy Participates in New Scientific Publication on AI in Drug Discovery

We’re proud to announce that Cancerappy has contributed to a recently published paper in Biomarker Research titled “Artificial intelligence in drug discovery and early development: current landscape and future opportunities”.

This publication explores how artificial intelligence is reshaping the drug development landscape—from identifying new therapeutic targets to optimizing clinical trial design. It highlights real-world applications and discusses the potential of AI to accelerate innovation, reduce development costs, and bring new therapies to patients faster and more efficiently.

At Cancerappy, we strongly believe in the value of AI to transform oncology drug discovery. Our involvement in this work reflects our commitment to advancing research and supporting the integration of cutting-edge technologies in cancer therapeutics.

Cancerappy: Using AI to Advance Cancer Research

Cancerappy: Using AI to Advance Cancer Research

Nov 4, 2024 | Artificial Intelligence, Big Data, Cancer Reseach

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis to developing more effective treatments with fewer side effects. We’re putting AI to work in areas like genomics, protein structure prediction, and drug discovery.

Here’s how AI drives our programs:

  • New Drug Development: AI speeds up drug discovery, making it faster, more cost-effective, and precise. It helps us screen drugs, predict multi-target effects, and find new uses for existing drugs.

  • Identifying Targets: AI enables us to design proteins and identify new therapeutic targets, opening doors to innovative treatments.

  • Handling Big Data: Cancer research generates huge data sets. AI helps us spot patterns, clean up data, and draw accurate conclusions.

  • Linking Data for Deeper Insights: By connecting data from diverse technologies, AI gives us a richer perspective and opens new research pathways.

At Cancerappy, AI is more than a tool—it’s a game-changer in our mission to make cancer treatments more effective and targeted.